Lily polysaccharide as well as preparation method and application thereof

The polysaccharides extracted and purified from the judan lily were solved, and the problems of poor efficacy and low safety of existing pulmonary fibrosis treatment drugs were significantly reduced, which significantly reduced the lung damage and fibrosis-related protein expression in mice with pulmonary fibrosis. Its therapeutic potential as a potential carbohydrate drug.

CN119060211APending Publication Date: 2024-12-03SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411221035.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing treatment drugs for pulmonary fibrosis have poor efficacy, low safety and obvious toxic and side effects, and lack natural, safe and effective prevention or treatment methods.

Method used

A polysaccharide was extracted from the lily of the juandan and purified by gradient elution method of boiling water extraction, dialysis, ethanol precipitation, anion exchange column and gel chromatography column to obtain a phenotype of fibroblasts with improved fibrosis and reduced fibrosis Polysaccharides expressed by related markers.

Benefits of technology

The polysaccharide significantly reduces lung damage and collagen deposition in mice induced by bleomycin, reduces the expression of fibrosis-related proteins, has potential treatment of pulmonary fibrosis, and does not affect hepatocyte growth viability in vitro.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005023041860000021
    Figure BDA0005023041860000021
  • Figure FDA0005023041850000011
    Figure FDA0005023041850000011
  • Figure HDA0005023041870000011
    Figure HDA0005023041870000011
Patent Text Reader

Abstract

The invention discloses lily polysaccharide as well as a preparation method and application thereof. According to a structural unit of the polysaccharide, 1-4 connected beta-galactopyranose (Galp), 1-3 connected beta-galactopyranose (Galp), 1-4 connected alpha-glucopyranose (Glcp), 1-6 connected alpha-glucopyranose (Glcp), 1-2 connected alpha-rhamnose pyranose (Rhap) and 1-6 connected beta-galactopyranose (Galp) are used as main chains, and the function of relieving pulmonary fibrosis is achieved; the traditional Chinese medicine composition is expected to become a medicine for treating pulmonary fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of Chinese herbal medicine polysaccharides, and in particular to a polysaccharide extracted from Lilium lancifolium Thunb., a preparation method thereof, a pharmaceutical composition thereof and use thereof in preparing a medicine for preventing and / or treating lung diseases, especially pulmonary fibrosis. Background Art

[0002] Pulmonary fibrosis (PF) refers to a large class of lung diseases characterized by fibroblast proliferation and accumulation of extracellular matrix, accompanied by inflammatory damage and tissue structure destruction, which can cause dyspnea, cough, hypoxemia, and hinder gas exchange, ultimately leading to respiratory failure.

[0003] At present, the causes of pulmonary fibrosis are mainly divided into: genetic factors, autoimmune diseases, risks brought by occupations, exposure to toxins, drugs, radiation, etc. In recent years, the number of people suffering from pulmonary fibrosis has increased sharply, and it has become one of the major public health issues affecting human health.

[0004] At present, glucocorticoids, cytotoxic drugs, immunosuppressants and anti-fibrotic drugs are still used clinically to treat pulmonary fibrosis, but these drugs have poor efficacy, low safety and obvious toxic side effects during the treatment process. Therefore, finding natural, safe and effective drugs to prevent or treat pulmonary fibrosis has become a research hotspot in the current field of fibrosis.

[0005] Lily is the flower bud of Lilium lancifolium Thunb., Lilium brownie F.E. Brown var. viridulum Baker or Lilium pumilum DC. of the Liliaceae family. It has the functions of moistening the lungs, clearing away heat and calming the mind. It is often used clinically to treat cough, dizziness, insomnia and pemphigus.

[0006] In China, lily has been widely used as a traditional medicine or dietary resource. Lily contains a variety of compounds such as polysaccharides, saponins, phenols, alkaloids and flavonoids.

[0007] At present, the research on lily plants is mainly concentrated on the bulbs. Lily bulb polysaccharides have pharmacological effects such as antioxidant, immunomodulatory, anti-tumor, and antibacterial effects, but there is less research on the polysaccharides in lily buds. Summary of the invention

[0008] The present invention adopts a simple and effective polysaccharide extraction method, and obtains a polysaccharide using Lilium lily as raw material. Pharmacological experiments show that the polysaccharide can improve the fibrotic phenotype of lung fibroblasts; in vivo animal experiment results show that the polysaccharide can significantly improve the lung damage and collagen deposition of mice with bleomycin-induced pulmonary fibrosis, and significantly reduce the expression of fibrosis-related markers. Therefore, the polysaccharide has a potential effect in treating pulmonary fibrosis and is expected to be developed into a carbohydrate drug against pulmonary fibrosis.

[0009] Based on this, an object of the present invention is to provide a lily polysaccharide.

[0010] Another object of the present invention is to provide a method for preparing the above polysaccharide.

[0011] Another object of the present invention is to provide a pharmaceutical composition comprising the polysaccharide.

[0012] Another object of the present invention is to provide use of the polysaccharide or a pharmaceutical composition containing the polysaccharide in preparing a drug for preventing and / or treating pulmonary fibrosis.

[0013] On the one hand, the present invention provides a polysaccharide, whose structural unit is composed of 1→4-linked β-galactopyranose (Galp), 1→3-linked β-galactopyranose (Galp), 1→4-linked α-pyranose glucose (Glcp), 1→6-linked α-pyranose glucose (Glcp), 1→2-linked α-pyranose rhamnose (Rhap) and 1→6-linked β-galactopyranose (Galp) as the main chain, and has the following structure:

[0014]

[0015] In the above structural formula, n represents the degree of polymerization. n is an integer greater than 1, such as 1, 2, 3, 4, 5, etc., but is not limited thereto.

[0016] In some embodiments, the weight average molecular weight (Mw) of the polysaccharide is 6-50 kDa, preferably 6-40 kDa, preferably 6-30 kDa, more preferably 6-20 kDa, especially 6-15 kDa, for example 7, 8, 9, 10, 11, 12, 13, 14 kDa.

[0017] In some embodiments, the number average molecular weight (Mn) of the polysaccharide is 6-45 kDa, preferably 6-35 kDa, preferably 6-25 kDa, more preferably 6-20 kDa, especially 6-12 kDa, such as 7, 8, 9, 10, 11 kDa.

[0018] In some embodiments, the molecular weight distribution (PDI, Mw / Mn) of the polysaccharide is 1.01-3, particularly 1.01-2, more particularly 1.01-1.8, 1.01-1.6 or 1.01-1.5, for example 1.1, 1.2, 1.3, 1.40, etc.

[0019] As can be seen from the structural formula, the polysaccharide structural unit according to the present invention includes a galactan domain and a glucan domain. In some embodiments, in the monosaccharide composition of the polysaccharide, the molar ratio of arabinose, galactose, glucose, xylose, rhamnose and glucuronic acid is 30-40:30-35:10-15:9.8-12:1.7-4.7:1.6-4.6, preferably 35-40:30-35:10-14:10-12:2-4:1.7-4.5, especially 38.4:32.8:12.7:10.3:2.6:2.7.

[0020] In some embodiments, the monosaccharide composition of the polysaccharide includes: 35-40% galactose, 30-35% arabinose, 10-15% glucose and 10-15% xylose. In addition, the monosaccharide composition of the polysaccharide contains 1-5% glucuronic acid and 1-5% rhamnose.

[0021] In some embodiments, the polysaccharide has substantially Figure 1 High performance liquid chromatogram shown.

[0022] In some embodiments, in the infrared spectrum of the polysaccharide, at 3382.42 cm -1 、2930.67cm -1 、1418.60cm -1 There is an absorption peak at the position, and the above absorption peak wave number may have a deviation of no more than 0.5%; preferably, the polysaccharide has substantially Figure 2 Infrared characteristic spectrum shown.

[0023] In some embodiments, the polysaccharide 13 In the C NMR spectrum, there are signal peaks at the following chemical shifts: δ110.49, δ108.75, δ108.35, δ107.64, δ105.61, δ105.21, δ104.97, δ104.65, δ103.77, δ102.89, δ102.57, δ101.21, δ100.83, δ100.10, δ100.01, δ98.88, and the above chemical shifts may have a deviation of no more than ±0.5. Preferably, the polysaccharide has substantially Figure 3 shown 13 C-NMR spectrum.

[0024] Another aspect of the present invention provides a method for preparing the above polysaccharide, comprising the following steps:

[0025] (1) Polysaccharide extraction:

[0026] The flowers of Lilium lily were extracted with boiling water, dialyzed, centrifuged and precipitated with ethanol, and the precipitate was collected to obtain crude polysaccharide.

[0027] (2) Primary purification of polysaccharides:

[0028] The crude polysaccharide prepared in step (1) is dissolved in water and then subjected to solid-liquid separation, the solution is gradient eluted using water and 0.05-0.4 M NaCl solution in sequence using an anion exchange column, and the elution component of 0.05 M NaCl solution is collected to obtain a preliminarily purified secondary crude polysaccharide;

[0029] (3) Secondary purification of polysaccharides:

[0030] The secondary crude polysaccharide is dissolved in water and then solid-liquid separation is performed. The solution is eluted on a gel chromatography column using a 0.2M NaCl solution, and the eluate is collected to obtain the target polysaccharide.

[0031] Preferably, step (1) further comprises, before the boiling water extraction, soaking the Lilium lily in an ethanol aqueous solution with a volume fraction of 90% or more, preferably 95% or more for 7 to 14 days (eg 7 days).

[0032] Preferably, in step (1), during the boiling water extraction, 15 to 30 times, preferably 20 times, of the weight of water is added; the boiling water extraction is performed 4 to 8 times, preferably 6 times, each time for 3 to 5 hours, preferably 4 hours.

[0033] Preferably, in step (1), the extracts are combined and concentrated, dialyzed, re-concentrated, centrifuged and then precipitated with alcohol. In particular, the dialysis is performed in water for 24 to 72 hours.

[0034] Preferably, in step (1), during the alcohol precipitation, 5 to 10 times, preferably 5 times, the volume of ethanol is added.

[0035] Preferably, in step (1), during the alcohol precipitation, the ethanol is an ethanol aqueous solution with a volume fraction of 70% or more, preferably an ethanol aqueous solution with a volume fraction of 85% or more, and more particularly an ethanol aqueous solution with a volume fraction of 95% or more.

[0036] Preferably, in step (1), the precipitate is washed with ethanol and acetone for 3 to 6 times, preferably 3 times.

[0037] Preferably, in step (2), the crude polysaccharide is dissolved in 10 to 15 times, preferably 12.5 times, the weight of water.

[0038] Preferably, in step (2), the anion exchange column is DEAE Sepharose TM The Fast Flow anion exchange column was gradient eluted with deionized water, 0.05 M, 0.1 M, 0.2 M and 0.4 M NaCl solutions in sequence.

[0039] Preferably, in step (3), the secondary crude polysaccharide is dissolved in about 10 to 30 times, preferably about 20 times, the weight of water.

[0040] Preferably, in step (3), the gel chromatography column is a Sephacryl HR S-200 gel chromatography column.

[0041] The experiments confirmed that the lily polysaccharide of the present invention can reduce bleomycin-induced pulmonary fibrosis, including restoring lung tissue morphology, reducing lung coefficient, reducing the expression of animal lung injury and fibrosis phenotype-related proteins, and does not affect the cell growth activity of hepatocyte LO2 in vitro, and can significantly inhibit the expression of fibrosis-related proteins. Therefore, the polysaccharide according to the present invention can become a potential carbohydrate drug for preventing and / or treating pulmonary fibrosis.

[0042] Therefore, another aspect of the present invention provides a pharmaceutical composition comprising the polysaccharide according to the present invention. The pharmaceutical composition may also comprise pharmaceutically acceptable excipients, such as adjuvants, diluents, disintegrants, surfactants, colorants, dyes, sweeteners, flavoring agents, lubricants, coating agents, etc., but is not limited thereto.

[0043] The pharmaceutical composition of the present invention may further include other active pharmaceutical ingredients as required. For example, it may include other components that prevent and / or treat pulmonary fibrosis to enhance the efficacy, or may include active pharmaceutical ingredients for treating other diseases to achieve combined treatment of multiple diseases, but the present invention is not limited thereto.

[0044] In another aspect, the present invention provides use of the polysaccharide or pharmaceutical composition according to the present invention in the preparation of a medicament for treating and / or preventing a lung disease. In particular, the lung disease is pulmonary fibrosis.

[0045] In another aspect, the present invention provides the use of the polysaccharide or pharmaceutical composition according to the present invention in the preparation of a drug having any one or more of the following effects:

[0046] (1) Inhibit the fibrosis process of lung fibroblasts;

[0047] (2) Reduce lung collagen deposition.

[0048] In another aspect, the present invention provides a kit comprising the polysaccharide or pharmaceutical composition according to the present invention. The kit may also comprise other components, such as a diluent, a drug delivery device, drug instructions, and the like.

[0049] In another aspect, the present invention provides a non-disease diagnosis and treatment method for inhibiting the fibrosis process of lung fibroblasts, the method comprising administering an effective amount of a polysaccharide or a pharmaceutical composition according to the present invention to a subject. The method can be used, for example, to study how to inhibit the fibrosis process of lung fibroblasts using a polysaccharide or a pharmaceutical composition according to the present invention in vitro, for example, using a polysaccharide or a pharmaceutical composition according to the present invention as an active ingredient, or as a positive control, but is not limited thereto.

[0050] The present invention has been described in detail above, but the above embodiments are only illustrative in nature and are not intended to limit the present invention. In addition, this article is not limited by any theory described in the above prior art or invention content or the following examples.

[0051] In this article, all features or conditions defined in the form of numerical ranges or percentage ranges are only for brevity and convenience. Accordingly, the description of numerical ranges or percentage ranges should be deemed to have covered and specifically disclosed all possible secondary ranges and individual values ​​within the range. In this article, under the premise that the purpose of the invention can be achieved, the numerical value should be understood as having the accuracy of the significant digits of the numerical value. For example, the number 40.0 should be understood to cover the range from 39.50 to 40.49. In addition to the working examples provided at the end of the detailed description, all numerical values ​​of parameters (e.g., quantities or conditions) in this application document (including the attached claims) should be understood in all cases as being modified by the term "approximately", regardless of whether "approximately" actually appears before the numerical value. "Approximately" means that the numerical value described allows for slight imprecision (some close to precision in this value; approximately or reasonably close to this value; approximately). If the imprecision provided by "approximately" is not understood in this ordinary meaning in the art, the "approximately" used herein at least represents the changes that can be produced by ordinary methods of measuring and using these parameters. For example, “about” can include a variation of less than or equal to 10%, less than or equal to 5%, less than or equal to 4%, less than or equal to 3%, less than or equal to 2%, less than or equal to 1%, or less than or equal to 0.5%, and in some aspects, a variation of less than or equal to 0.1%.

[0052] The above description is intended to be illustrative rather than restrictive. For example, the above embodiments (or one or more features thereof) may be used in combination with each other. For example, those of ordinary skill in the art may use other embodiments when reading the above description. In addition, in the above embodiments, various features may be grouped together to simplify the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 This is a characteristic HPLC chromatogram of the Lilium lily polysaccharide L005-B prepared in Example 1;

[0054] Figure 2 This is a characteristic infrared spectrum of the Lilium lily polysaccharide L005-B prepared in Example 1;

[0055] Figure 3 The polysaccharide L005-B prepared in Example 1 is 1 H NMR (A) and 13 C NMR (B) spectrum;

[0056] Figure 4 After the bleomycin-induced pulmonary fibrosis model was treated with the lily polysaccharide L005-B prepared in Example 1, the mouse lung tissue morphology (A), lung weight coefficient bar graph (B) and representative graphs of hematoxylin-eosin staining and Masson staining (C) (where **p<0.01, ***p<0.001, ****p<0.0001, indicating the degree of significant difference compared with the control group);

[0057] Figure 5 The immunoblot image of lily polysaccharide L005-B prepared in Example 1 on alpha-smooth muscle actin (α-SMA), collagen Ⅰ and fibronectin in mouse lung tissue in the bleomycin-induced pulmonary fibrosis model;

[0058] Figure 6 This is a bar graph showing the effect of the lily polysaccharide L005-B prepared in Preparation Example 1 on the growth activity of liver cells LO2 using a CCK-8 cell proliferation and toxicity detection experiment;

[0059] Figure 7 The immunoblot diagram of the effect of lily polysaccharide L005-B prepared in Example 1 on the protein expression levels of α-smooth muscle actin (α-SMA), collagen Ⅰ, and fibronectin in TGF-β-induced lung fibroblast MRC5 cells (+ represents addition, - represents no addition). DETAILED DESCRIPTION

[0060] The present invention is described in detail below by examples. It should be noted that the examples are intended to better explain the present invention, rather than to limit its scope. Various variations and modifications are permitted without departing from the spirit and scope of the present invention. Unless otherwise specified, the raw materials and equipment used in the specific embodiments of the present invention are all conventional raw materials and reagents in this area, and can be obtained by purchasing commercially available products.

[0061] Example 1 Preparation of Lilium lily polysaccharide L005-B

[0062] (1) Extraction and separation of polysaccharides

[0063] 3kg of Lilium lily (origin in Zhejiang) was soaked in 95% ethanol by volume for 14 days and then air-dried. 30L of water was added to the medicinal material and extracted by boiling water extraction method for 4 hours each time for a total of 8 times. The sugar content of the extract was detected by sulfuric acid-phenol method until the color reaction was not obvious. The extract was concentrated to 1 liter and dialyzed in convection water for 48 hours, and then the dialyzate was concentrated and centrifuged to remove the precipitate. 95% ethanol by volume was added to the supernatant for alcohol precipitation. While adding ethanol, it was stirred in the same direction. The volume ratio of the extract to ethanol was 1:4 (v / v), and it was allowed to stand overnight. The upper ethanol was discarded, the precipitate was collected by centrifugation, and then the precipitate was washed alternately with ethanol and acetone three times. The precipitate was redissolved in water and freeze-dried to obtain 132g of Lilium lily crude polysaccharide LLP (the yield was 4.4% relative to the weight of the dry medicinal material).

[0064] (2) Purification of polysaccharides

[0065] Dissolve 50 g of crude polysaccharide LLP in 500 mL of deionized water, heat and stir to dissolve overnight. Centrifuge to obtain the supernatant and pass it through DEAE Sepharose TM Fast Flow anion exchange column was used for separation. Deionized water and 0.05M NaCl solution were used for elution in turn, the flow rate was set to 100mL / min, and the eluate was collected in a 500mL conical flask. 100μL of solution was taken from each bottle, the color was developed using the sulfuric acid-phenol method, and its absorbance was detected at 490nm, and an elution curve of absorbance and elution volume was drawn. The components were collected according to the elution curve, concentrated under reduced pressure, dialyzed and freeze-dried, and finally the component of 0.05M NaCl eluate was obtained, which was named secondary crude polysaccharide LLP005 (2.4g).

[0066] Dissolve 200 mg of secondary crude polysaccharide LLP005 in 4 mL of deionized water and centrifuge (4000 r / min). Take the supernatant and load it on a Sephacryl S-200 HR gel column. Use 0.2 M NaCl solution for elution. Control the flow rate to 5 mL / 15 min, and collect the eluate by an automatic collector. Use sulfuric acid-phenol method to develop the color and detect the absorbance, and draw an elution curve. Collect the desired separation components, concentrate, dialyze and freeze-dry to obtain uniform polysaccharide L005-B (153 mg).

[0067] Example 2 Structural Identification of Polysaccharide L005-B

[0068] The uniform polysaccharide L005-B from Lilium lily flowers obtained according to the method of Example 1 was identified. The specific analysis method and results are as follows.

[0069] (1) Polysaccharide homogeneity and molecular weight determination

[0070] The average relative molecular mass of the polysaccharide sample L005-B from Lilium lily was determined by high performance gel permeation chromatography (HPGPC).

[0071] The polysaccharide L005-B from Lilium lily was synthesized by tandem with Sugar KS-802 (exclusion limit 1x10 4 Da) and KS-804 (exclusion limit 4x10 5 Da) analytical gel column was used for analysis. The chromatographic conditions were as follows: the mobile phase was 0.1 M NaNO3, the flow rate was 0.5 mL / min, the column temperature was 40°C, an Agilent 1260 liquid chromatograph was used, and the detectors were a differential detector and an ultraviolet detector (detection wavelength was 280 nm).

[0072] like Figure 1 The characteristic spectrum shown shows that the weight average molecular weight of the Lilium lily polysaccharide L005-B is about 11.7 kDa, the number average molecular weight is about 9000 kDa, and the molecular weight distribution (Mw / Mn) is about 1.30.

[0073] (2) Determination of monosaccharide composition by PMP-HPLC derivatization

[0074] Preparation of monosaccharide standards:

[0075] The nine monosaccharide standards are D-mannose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-glucose, D-galactose, L-xylose, L-arabinose and L-fucose.

[0076] 9 mg of nine monosaccharides were dissolved in 1 mL of deionized water respectively, and then 100 μL of the above monosaccharide solutions were taken and mixed to obtain standard solutions with a concentration of 1 mg / mL for each of the nine monosaccharides.

[0077] Take 50 μL of the above standard solution in a 2 mL EP tube, add 50 μL of 0.6 M NaOH solution and 100 μL of 0.5 M 1-phenyl-3-methyl-5-pyrazolone (PMP) methanol solution, react in a 70 ° C water bath for 100 min, add 100 μL of 0.3 M hydrochloric acid solution to the solution to neutralize and end the reaction, then add 700 μL of deionized water and 1 mL of chloroform, vortex for 30 min, let stand for 30 min, then centrifuge and draw 800 μL of the upper aqueous phase solution into a new 2 mL EP tube. Add chloroform again, extract twice, centrifuge and take the upper aqueous phase, filter through a 0.22 μm microporous membrane and put into a liquid phase vial to obtain a monosaccharide standard.

[0078] Sample preparation:

[0079] Take 2-3 mg of dried Lilium lily polysaccharide L005-B sample in a pear-shaped flask, add 2 mL of deionized water and 2 ml of 4M trifluoroacetic acid, seal and hydrolyze at 110 ° C for 4 hours, cool the sample to room temperature, repeatedly add methanol to evaporate the excess trifluoroacetic acid, add 200 μL of deionized water to re-dissolve the sample, take out 50 μL and add it to a 2 mL EP tube. The subsequent steps (derivation and extraction) are the same as the standard.

[0080] Preparation of mobile phase:

[0081] Weigh 13.6 g of potassium dihydrogen phosphate and 1.8 g of sodium hydroxide and dissolve them in 2 L of Milli-Q water. Pass the aqueous phase through a filter membrane to obtain solution ①. Measure acetonitrile (HPLC grade) and mix it with solution ① in a ratio of 17:83 (v / v). Ultrasonicate for 30 min to mix them evenly to obtain a mobile phase.

[0082] HPLC assay conditions: the analytical column was Agilent XDB-C18, 4.6×250 mm, 5 μm; the column temperature was set to 35°C, the flow rate was 1 mL / min, the UV absorption wavelength was 245 nm, and the injection volume was 10 μL.

[0083] The results of monosaccharide composition analysis showed that in the monosaccharide composition of L005-B, the molar ratio of arabinose, galactose, glucose, xylose, rhamnose and glucuronic acid was 38.4:32.8:12.7:10.3:2.6:2.7.

[0084] (3) Infrared spectroscopy analysis

[0085] About 2 mg of polysaccharide sample was taken and the infrared spectrum of the polysaccharide sample was measured by potassium bromide (KBr) tablet method. Figure 2 ), at 3382.42cm -1、2930.67cm -1 、1418.60cm -1 There is an absorption peak at 3382.42cm. The above absorption peak wave number may have a deviation of no more than 0.5%. -1 There is a strong and broad absorption peak around 2930.67cm, which is the OH stretching vibration of the hydroxyl group and the existence of intermolecular hydrogen bonds. -1 There are absorption peaks on both sides, which are the signals of saturated CH stretching vibration (absorption peaks of -CH and -CH2) on the sugar ring. -1 There are characteristic absorption bands, which may be caused by the COC stretching vibration in the carboxylic acid ester, proving the possibility of the presence of acyl groups.

[0086] (4) Nuclear Magnetic Resonance Analysis

[0087] Take 35 mg of Lilium lily polysaccharide L005-B sample, dissolve it in 0.5 mL D2O, and add 1.5 μL acetone as internal standard (δ H =2.29ppm, δ C =31.5ppm), and the one-dimensional 1 H NMR and 13 C NMR. The results are as follows Figure 3 shown.

[0088] Figure 3 A represents polysaccharide L005-B 1 H NMR spectrum, there are signal peaks at the following chemical shifts: 5.47ppm, 5.35ppm, 5.32ppm, 5.30ppm, 5.27ppm, 5.22ppm, 5.15ppm, 5.02ppm, 4.71ppm, 4.61ppm, 4.60ppm, 4.55ppm, 4.54ppm. Among them, the signal peaks at 5.47ppm and 5.02ppm are the anomeric hydrogen signals of glucose residues; 5.35ppm is the anomeric hydrogen signal of uronic acid; 5.32ppm is the anomeric hydrogen signal of rhamnose residues; the signal peaks at 5.30-5.15ppm are the anomeric hydrogen signals of arabinose residues; 4.71-4.54 are the anomeric hydrogen signals of galactose and xylose residues. Figure 3 B in the figure indicates polysaccharide L005-B 13C NMR spectrum, with signal peaks at the following chemical shifts: 110.49ppm, 108.75ppm, 108.35ppm, 107.64ppm, 105.61ppm, 105.21ppm, 104.97ppm, 104.65ppm, 103.77ppm, 102.89ppm, 102.57ppm, 101.21ppm, 100.83ppm, 100.10ppm, 100.01ppm, 98.88ppm. The above chemical shifts may have a deviation of no more than ±0.5. Among them, 110.49-107.64ppm is the anomeric carbon signal of arabinose residue; 105.61 -103.77ppm is the anomeric carbon signal of galactose residue; 102.89-102.57ppm is the anomeric carbon signal of xylose; 101.21 -100.10ppm is the anomeric carbon signal of glucose; 100.01ppm is the anomeric carbon signal of rhamnose; 98.88ppm is the anomeric carbon signal of uronic acid.

[0089] Example 3: Study on the anti-pulmonary fibrosis activity of polysaccharide L005-B

[0090] (1) Effects of lily polysaccharide L005-B on lung tissue morphology, lung tissue coefficient and collagen deposition in mice using a bleomycin-induced pulmonary fibrosis model

[0091] This animal experiment complied with the Guide for the Care and Use of Laboratory Animals and was approved by the Animal Ethics Committee of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Thirty-six 8-week-old male C57BL / 6 mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. and housed in the clean room of the Animal Medicine Facility of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, with free access to food and water, room temperature of 22±1℃, indoor relative humidity of 65±5%, and a light / dark cycle of 12 / 12h.

[0092] In this experiment, mice were randomly divided into 3 groups, 6 mice in the control group, 6 mice in the model group, and 24 mice in the experimental group. After 7 days of adaptation, 0.8 mg / kg (prepared with 0.9% saline) of bleomycin (purchased from CSNpharm) solution was administered tracheally to the model group and the experimental group; an equal volume of 0.9% saline was administered tracheally to 6 mice in the control group.

[0093] One week after modeling, the experimental groups were randomly divided into four groups, A, B, C, and D, with 6 mice in each group. Group A was given 10 mg / kg L005-B polysaccharide; Group B was given 30 mg / kg L005-B polysaccharide; Group C was given 90 mg / kg L005-B polysaccharide; Group D was the positive drug control group, which was given 100 mg / kg nintedanib (purchased from MCE) by intragastric administration every day for two weeks. The control group and the model group were given an equal volume of normal saline.

[0094] Two weeks after administration, the mice were sacrificed, the lung weights of the mice were recorded, the lung tissue morphology of the mice in each group was observed, and the left lung lobe was taken and fixed with 4% paraformaldehyde for 48 hours, followed by hematoxylin-eosin staining and Masson staining. Figure 4 .

[0095] like Figure 4 As shown in A, after oral administration of L005-B, the appearance of the lungs of mice in the high-dose group was close to that of the control group. The surface gradually returned to being smooth and rosy, and the color also improved. However, compared with the control group, the softness and elasticity of the tissue were still insufficient.

[0096] like Figure 4 As shown in C, the results of hematoxylin-eosin staining showed that the lung lesions of mice in the medium and high dose groups of L005-B were significantly alleviated, slight dilation of interstitial blood vessels and mild alveolar inflammation were observed, the degree of fibrosis of the alveolar wall was significantly reduced, and no extensive inflammatory infiltration was observed. The therapeutic effect of the high dose group was equivalent to that of the positive drug nintedanib group; Masson staining results showed that a large number of proliferating blue collagen fibers were observed in the bronchial adventitia, tissues around vascular branches, and significantly thickened alveolar septa in the model group. In contrast, the alveolar integrity in the lung tissue of mice in the low, medium, and high dose groups of L005-B intervention gradually improved, the fibrous tissue clumps were significantly reduced, and the inhibition of collagen deposition was more obvious.

[0097] The lung weight coefficient (lung tissue weight / mouse body weight) is as follows Figure 4 As shown in B, compared with the control group, the lung coefficient of mice in the model group was significantly increased, and the lung weight coefficients of the low-, medium-, and high-dose intervention groups of L005-B polysaccharide were significantly reduced in a concentration-dependent manner. The improvement effect of the high-dose group was equivalent to that of the positive drug nintedanib group.

[0098] The above results indicate that lily polysaccharide L005-B can effectively alleviate pulmonary fibrosis lesions, reduce collagen fiber proliferation, and slow down the progression of pulmonary fibrosis.

[0099] (2) Western blotting assay to detect the effect of L005-B polysaccharide on the levels of proteins related to fibrosis phenotype in mouse lungs

[0100] Two weeks after administration, the mice were sacrificed, and part of the lung tissue was taken to extract the whole tissue protein using a tissue extraction kit (purchased from Shenggong Biotechnology Co., Ltd.). Immunoblotting was used to detect the protein expression of alpha-smooth muscle actin (α-SMA), collagen Ⅰ, and fibronectin.

[0101] The results are as follows Figure 5As shown, lily polysaccharide L005-B can inhibit the expression of proteins related to fibrosis phenotype.

[0102] (3) CCK-8 assay to detect the effect of lily polysaccharide L005-B on the growth activity of hepatocyte LO2

[0103] An appropriate number of LO2 cells were inoculated in a 96-well plate, with 5 replicate wells per group. After the cells adhered to the wall, the original cell culture medium was discarded, and normal liver cells LO2 were incubated with different concentrations of L005-B (0, 0.2, 0.4, 0.6, 0.8 and 1 mg / mL). After incubation of the drug to be tested for 48 hours, 10 μL of CCK-8 enhanced solution (purchased from Dalian Meilun Company) was added to each well, and the absorbance was detected at 450nm using an ELISA reader after continuing to culture for 1 hour.

[0104] The cell viability calculation formula is as follows: cell viability = (OD dosing well-OD zeroing well) / (OD blank well-OD zeroing well) × 100%.

[0105] The results show Figure 6 As shown, compared with the blank control group LO2 cells, the addition of different concentrations of lily polysaccharide L005-B had no effect on their growth activity, and there was no significant difference, indicating that L005-B had no cytotoxicity.

[0106] (4) Western blotting experiments were used to detect the effect of lily polysaccharide L005-B on the expression of fibrosis phenotype-related proteins in lung fibroblasts MRC5

[0107] Human lung fibroblasts MRC5 were cultured in DMEM medium containing 10% fetal bovine serum (purchased from Gibco, USA), 100U / mL penicillin and 100μg / mL streptomycin in a volume ratio of 1:1. MRC5 cells in the logarithmic growth phase were seeded in a 6-well plate at an appropriate density. After culturing for 24 hours, they were treated with 0.25, 0.5 and 1mg / mL of lily polysaccharide L005-B and positive drug 1μg / mL nintedanib, and TGF-β recombinant protein (purchased from Abclonal) was added at a concentration of 5ng / ml for stimulation. After culturing for 48 hours, the supernatant was discarded, the cells were rinsed with pre-cooled PBS, and the cells were lysed on ice for 20 minutes with cell lysis buffer (purchased from Biyuntian Company, item number: P0013D), and the supernatant was collected by centrifugation. After adding 5× loading buffer (prepared with 10 g sodium dodecyl sulfate, 0.5 g bromophenol blue, 5 ml β-mercaptoethanol and 50 ml glycerol, and dilute to 100 ml with water), the protein was denatured in a metal heater for 10 min, cooled and stored at -80°C. Immunoblotting was used to detect the protein expression of α-smooth muscle actin (α-SMA), collagen I, and fibronectin.

[0108] The results are as follows Figure 7 As shown, lily polysaccharide L005-B can significantly inhibit the expression of fibrosis-related proteins.

[0109] In summary, the test results of the embodiment show that lily polysaccharide L005-B can reduce bleomycin-induced pulmonary fibrosis, including restoring lung tissue morphology, reducing lung coefficient, and reducing the expression of animal lung injury and fibrosis phenotype-related proteins. In addition, it does not affect the cell growth activity of hepatocytes LO2 in vitro, and lily polysaccharide L005-B can significantly inhibit the expression of fibrosis-related proteins. Therefore, the polysaccharide component L005-B can become a potential carbohydrate drug for preventing and / or treating pulmonary fibrosis.

Claims

1. A polysaccharide, wherein the structural unit is composed of 1→4 linked β-galactopyranose (Galp), 1→3 linked β-galactopyranose (Galp), 1→4 linked α-glucose pyranose (Glcp), 1→6 linked α-glucose pyranose (Glcp), 1→2 linked α-rhamnose pyranose (Rhap) and 1→6 linked β-galactopyranose (Galp) as the main chain, and has the following structure:

2. The polysaccharide according to claim 1, It is characterized in that The weight average molecular weight Mw of the polysaccharide is 6-50 kDa, preferably 6-40 kDa, preferably 6-30 kDa, more preferably 6-20 kDa, especially 6-15 kDa; the number average molecular weight Mn of the polysaccharide is 6-45 kDa, preferably 6-35 kDa, preferably 6-25 kDa, more preferably 6-20 kDa, especially 6-12 kDa; the molecular weight distribution Mw / Mn of the polysaccharide is 1.01-3, especially 1.01-2, more especially 1.01-1.8, 1.01-1.6 or 1.01-1.5; and / or In the monosaccharide composition of the polysaccharide, the molar ratio of arabinose, galactose, glucose, xylose, rhamnose and glucuronic acid is 30-40:30-35:10-15:9.8-12:1.7-4.7:1.6-4.6, preferably 35-40:30-35:10-14:10-12:2-4:1.7-4.5, especially 38.4:32.8:12.7:10.3:2.6:2.7; and / or The monosaccharide composition of the polysaccharide includes: 35-40% galactose, 30-35% arabinose, 10-15% glucose and 10-15% xylose.

3. The polysaccharide according to claim 1, It is characterized in that The polysaccharide has a high performance liquid chromatogram substantially as shown in Figure 1; and / or In the infrared spectrum of the polysaccharide, at 3382.42 cm -1 、2930.67cm -1 、1418.60cm -1 There is an absorption peak at; preferably, the polysaccharide has an infrared characteristic spectrum substantially as shown in Figure 2; and / or The polysaccharide 13 In the C NMR spectrum, there are signal peaks at the following chemical shifts: δ110.49, δ108.75, δ108.35, δ107.64, δ105.61, δ105.21, δ104.97, δ104.65, δ103.77, δ102.89, δ102.57, δ101.21, δ100.83, δ100.10, δ100.01, δ98.88; preferably, the polysaccharide has a substantially chemical shift as shown in FIG3 13 C-NMR spectrum.

4. A method for preparing polysaccharides, comprising the following steps: (1) Polysaccharide extraction: The flowers of Lilium lily are extracted with boiling water, dialyzed and centrifuged, and ethanol precipitated, and the precipitate is collected to obtain the crude polysaccharide of Lilium lily. (2) Primary purification of polysaccharides: The crude polysaccharide of Lilium lily prepared in step (1) is dissolved in water and then subjected to solid-liquid separation, and the solution is gradient eluted using water and 0.05-0.4 M NaCl solution in sequence using an anion exchange column, and the elution component of 0.05 M NaCl solution is collected to obtain a preliminarily purified secondary crude polysaccharide; (3) Secondary purification of polysaccharides: The secondary crude polysaccharide is dissolved in water and then solid-liquid separation is performed. The solution is eluted on a gel chromatography column using a 0.2 M NaCl solution, and the eluate is collected to obtain the target polysaccharide.

5. The method according to claim 4, It is characterized in that Step (1) further comprises, before the boiling water extraction, soaking the Lilium lily in an ethanol aqueous solution having a volume fraction of 90% or more, preferably 95% or more, for 7 to 14 days; and / or In step (1), during the boiling water extraction, 15 to 30 times of water is added; the boiling water extraction is performed 4 to 8 times, each time for 3 to 5 hours; and / or In step (1), the extracts are combined and concentrated, dialyzed, re-concentrated, centrifuged and then precipitated with alcohol; in particular, the dialysis is performed in water for 24 to 72 hours; and / or In step (1), during the alcohol precipitation, 5 to 10 times of ethanol is added; preferably, the ethanol is an ethanol aqueous solution with a volume fraction of 70% or more, preferably an ethanol aqueous solution with a volume fraction of 85% or more, more particularly an ethanol aqueous solution with a volume fraction of 95% or more; and / or In step (1), the precipitate is washed 3 to 6 times with ethanol and acetone; and / or In step (2), the crude polysaccharide is dissolved in 10 to 15 times the weight of water; and / or In step (2), the anion exchange column is DEAE Sepharose TM Fast Flow anion exchange column, gradient elution with deionized water, 0.05M, 0.1M, 0.2M and 0.4M NaCl solution; and / or In step (3), the secondary crude polysaccharide is dissolved in 10 to 30 times the weight of water; and / or In step (3), the gel chromatography column is a Sephacryl HR S-200 gel chromatography column.

6. A pharmaceutical composition comprising the polysaccharide according to any one of claims 1 to 3 or the polysaccharide prepared by the method according to claim 4 or 5 as an active ingredient; and optionally a pharmaceutically acceptable excipient.

7. Use of the polysaccharide according to any one of claims 1 to 3, or the polysaccharide prepared by the method according to claim 4 or 5, or the pharmaceutical composition according to claim 6 in the preparation of a drug for treating and / or preventing lung diseases, especially pulmonary fibrosis.

8. Use of the polysaccharide according to any one of claims 1 to 3, or the polysaccharide prepared by the method according to claim 4 or 5, or the pharmaceutical composition according to claim 6 in the preparation of a drug having any one or more of the following effects: (1) Inhibit the fibrosis process of lung fibroblasts; (2) Reduce lung collagen deposition.

9. A kit comprising the polysaccharide according to any one of claims 1 to 3 or the polysaccharide prepared by the method according to claim 4 or 5, or the pharmaceutical composition according to claim 6.

10. A non-disease diagnosis and treatment method for inhibiting the fibrosis process of lung fibroblasts, It is characterized in that The method comprises administering to the subject an effective amount of the polysaccharide according to any one of claims 1 to 3, or the polysaccharide prepared by the method according to claim 4 or 5, or the pharmaceutical composition according to claim 6.